Guide

What to consider when building a channel strategy for a rare disease product

A checklist for biopharma companies

Evaluating channel strategy options for a rare disease product is an essential element of commercialization. Biopharma companies should ask themselves these five questions to ensure their novel therapy reaches the right patients at the right time.

Enter your information below to download the checklist. 

Pardot Form

Related resources

Webinar

Building HTA‑ready evidence with AI‑enabled early modeling
meeting

Webinar

Real-world solutions for regulatory publishing challenges

Article

Harmonizing and safeguarding global and local pharmacovigilance processes